
### H1 2022 vs H1 2021 Overview


# **≣**IQVIA

## Total number of single drug assessments from January until June



• We no longer see a COVID-19 impact on the workload of the national HTA bodies


#### **Oncology vs Non-oncology**



• Year-on-year growth can be observed in oncology with 25% in the first half of 2021 and 34% H1 this year

 In non-oncology 15% decrease has been observed this first half, compared to a big growth the previous year (51%)

**Recommendations in Oncology vs Non-oncology** 



#### Countries with biggest changes in total SDA H1 2022 vs H1 2021

• The SDAs in Singapore jumped from 15 in January-June 2021 to 101 for the same period in 2022

- A reason for the increase in the total number of SDAs in Spain could be the establishment of the new policy of transparency and prioritization policy in the country
- The biggest decrease in the Big 5 is in the Italian HTA agency with 83% which can be recovered until the end of the year

#### SDAs in Singapore 2022



- More than half of the SDAs in Singapore were negative. Main rejection key driver is Not cost-effectiveness of the intervention.
- · For reference, in 2021 there were 8 (53%) negative and 7 (47%) positive recommendations

Source: IQVIA HTA Accelerator. | All SDAs from January 2022 till the end of June 2022 are included. | This analysis includes only reports with clear positive, restricted/conditioned or negative recommendations; Positive recommended without any restrictions to the full licensed indication. Restricted/Conditioned = The technology has been recommended but with restrictions to specific patient populations; Negative recommendation = the technology has on the technology has on the econology has not been recommended Abtreviations: H1= Half 1; HTA = Health technology assessment; Q1= Quarter 1; Q2= Quarter 2; SDA = Single drug assessment;